Exploring the mechanism of the anti-hypertension properties of Morinda citrifolia through a bioinformatics approach


  • Dian Laila Purwaningroom Faculty of Health Science, Muhammadiyah University, Ponorogo, Indonesia
  • Sholihatul Maghfirah Faculty of Health Science, Muhammadiyah University, Ponorogo, Indonesia
  • Muhaimin Rifai Brawijaya university
  • Nashi widodo Brawijaya university




Noni, Morinda citrifolia, ACE, Anti-hypertension, Bioinformatic


Traditionally, noni (Morinda citrifolia L.) has been used as a treatment for hypertension in tropical countries.  Many have proven that noni extract reduces blood pressure and is relatively safe (non-toxic) to the liver and kidney in lab animals. This extract is an angiotensin converting enzyme (ACE) inhibitor and plays a pivotal role in controlling blood pressure. However, researchers have yet to be able to identify the active compound that functions as the ACE inhibitor. Therefore, the objective of this study was to identify the active compound that acts as the ACE inhibitor as well as other anti-hypertension mechanisms using a bioinformaticsapproach. An enzyme activity analysis showed that noni methanol extract blocked ACE activity based on a comparable dosage (dose-dependent) with commercially anti-hypertension drugs. STITC and the STRINGdb database were used  to identify the interaction between the M. citrifolia active compound with proteins target, revealing three active compounds, namely linoleic acid, palmitate and oleic acid, which were bound to PPARA protein, and NOS3, which is predicted as a regulator of blood pressure through the PPARA pathway. The findings showed that M. citrifolia has numerous active compounds containing multiple protein targets. However, in vitro and in vivo research should be conducted to provide evidence for the mechanism.


Carrillo-López, A. & Yahia, E. M. 4 - Noni (Morinda citrifolia L.). in Postharvest Biology and Technology of Tropical and Subtropical Fruits (ed. Yahia, E. M.) 51–64e (Woodhead Publishing, 2011). doi:10.1533/9780857092618.51

Wang, M. Y. & Su, C. Cancer preventive effect of Morinda citrifolia (Noni). Ann. N. Y. Acad. Sci. 952, 161–168 (2001).

Yang, S.-C., Chen, T.-I., Li, K.-Y. & Tsai, T.-C. Change in Phenolic Compound Content, Reductive Capacity and ACE Inhibitory Activity in Noni Juice during Traditional Fermentation. 15, (2007).

Palu, ’Afa Kehaati, Santiago, R. A., West, B. J., Kaluhiokalani, N. & Jensen, J. The Effects of Morinda citrifolia L. Noni on High Blood Pressure: A Mechanistic Investigation and Case Study. in Functional Food and Health 993, 446–453 (American Chemical Society, 2008).

Algenstaedt, P., Stumpenhagen, A. & Westendorf, J. The Effect of Morinda citrifolia L. Fruit Juice on the Blood Sugar Level and Other Serum Parameters in Patients with Diabetes Type 2. Evidence-Based Complementary and Alternative Medicine (2018). doi:10.1155/2018/3565427

Ali, M., Kenganora, M., Manjula, S. & Manjula, S. Health Benefits of Morinda citrifolia (Noni): A Review. Pharmacogn. J. 8, 321–334 (2016).

West, B. J., Deng, S., Isami, F., Uwaya, A. & Jensen, C. J. The Potential Health Benefits of Noni Juice: A Review of Human Intervention Studies. Foods 7, (2018).

Inada, A. C. et al. Morinda citrifolia Linn. (Noni) and Its Potential in Obesity-Related Metabolic Dysfunction. Nutrients 9, 540 (2017).

Wigati, D., Anwar, K., Sudarsono, null & Nugroho, A. E. Hypotensive Activity of Ethanolic Extracts of Morinda citrifolia L. Leaves and Fruit in Dexamethasone-Induced Hypertensive Rat. J. Evid.-Based Complement. Altern. Med. 22, 107–113 (2017).

Sousa, B. C. de et al. Effects of short-term consumption of Morinda citrifolia (Noni) fruit juice on mice intestine, liver and kidney immune modulation. Food Agric. Immunol. 28, 528–542 (2017).

Pandy, V., Narasingam, M., Kunasegaran, T., Murugan, D. D. & Mohamed, Z. Effect of Noni (Morinda citrifolia Linn.) Fruit and Its Bioactive Principles Scopoletin and Rutin on Rat Vas Deferens Contractility: An Ex Vivo Study. The Scientific World Journal (2014). doi:10.1155/2014/909586

Sayed-Tabatabaei, F. a., Oostra, B. a., Isaacs, a., Van Duijn, C. M. & Witteman, J. C. M. ACE polymorphisms. Circ. Res. 98, 1123–1133 (2006).

Majumder, K. et al. Egg-derived ACE-inhibitory peptides IQW and LKP reduce blood pressure in spontaneously hypertensive rats. J. Funct. Foods 13, 50–60 (2015).

Lacroix, I. M. E., Meng, G., Cheung, I. W. Y. & Li-chan, E. C. Y. Do whey protein-derived peptides have dual dipeptidyl-peptidase IV and angiotensin I-converting enzyme inhibitory activities ? J. Funct. Foods 21, 87–96 (2016).

Ngo, D., Ryu, B. & Kim, S. Active peptides from skate ( Okamejei kenojei ) skin gelatin diminish angiotensin-I converting enzyme activity and intracellular free radical-mediated oxidation. Food Chem. 143, 246–255 (2014).

Kleekayai, T. et al. Extraction of antioxidant and ACE inhibitory peptides from Thai traditional fermented shrimp pastes. FOOD Chem. 176, 441–447 (2015).

Salampessy, J., Reddy, N., Kailasapathy, K. & Phillips, M. Functional and potential therapeutic ACE-inhibitory peptides derived from bromelain hydrolysis of trevally proteins. J. Funct. Foods 14, 716–725 (2015).

Balti, R. et al. Nine novel angiotensin I-converting enzyme ( ACE ) inhibitory peptides from cuttlefish ( Sepia officinalis ) muscle protein hydrolysates and antihypertensive effect of the potent active peptide in spontaneously hypertensive rats. Food Chem. 170, 519–525 (2015).

Zamora, S. G. & Parodi, R. Cough and angioedema in patients receiving angiotensin-converting enzyme inhibitors. Are they always attributable to medication? Rev. Argent. Cardiol. 79, 157–163 (2011).

Masuyer, G., Schwager, S. L. U., Sturrock, E. D., Isaac, R. E. & Acharya, K. R. Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Sci. Rep. 2, 717–717 (2012).

Moreau, M. E. et al. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 99, 6–38 (2005).

Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62, 720–733 (2015).

Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62, 720–733 (2015).

Yousefipour, Z. & Newaz, M. PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats. Acta Pharmacol. Sin. 35, 476–82 (2014).

Rőszer, T. & Ricote, M. PPARs in the Renal Regulation of Systemic Blood Pressure. PPAR Research (2010). doi:10.1155/2010/698730


Sugawara, A. et al. Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease. Endocr. J. 57, 847–852 (2010).

Hansmann, G. & Zamanian, R. T. PPARγ Activation: A Potential Treatment For Pulmonary Hypertension. Sci. Transl. Med. 1, 12ps14-12ps14 (2009).

Chandra, M., Miriyala, S. & Panchatcharam, M. PPARγ and Its Role in Cardiovascular Diseases. PPAR Research (2017). doi:10.1155/2017/6404638

Sen, U. & Tyagi, S. C. Homocysteine and Hypertension in Diabetes: Does PPARγ Have a Regulatory Role? PPAR Research (2010). doi:10.1155/2010/806538

Ketsawatsomkron, P. et al. Does Peroxisome Proliferator-activated Receptor-γ (PPARγ) Protect from Hypertension Directly through Effects in the Vasculature? J. Biol. Chem. 285, 9311–9316 (2010).

Usuda, D. & Kanda, T. Peroxisome proliferator-activated receptors for hypertension. World J. Cardiol. 6, 744–754 (2014).

Sutliff, R. L., Kang, B.-Y. & Hart, C. M. PPARγ as a potential therapeutic target in pulmonary hypertension. Ther. Adv. Respir. Dis. 4, 143–160 (2010).

Stump, M., Mukohda, M., Hu, C. & Sigmund, C. D. PPARγ Regulation in Hypertension and Metabolic Syndrome. Curr. Hypertens. Rep. 17, 89 (2015).

Żak, I. et al. Contemporaneous carrier-state of two or three “proatherosclerotic” variants of APOE, ICAM1, PPARA and PAI-1 genes differentiate CAD patients from healthy individuals. Clin. Chim. Acta 362, 110–118 (2005).

Afendi, F. M. et al. KNApSAcK Family Databases: Integrated Metabolite–Plant Species Databases for Multifaceted Plant Research. Plant Cell Physiol. 53, e1–e1 (2012).

Kim, S. et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 47, D1102–D1109 (2019).

Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 30, 2785–2791 (2009).

Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. Clifton NJ 1263, 243–250 (2015).

Dassault System BIOVIA. Discovery Studio. (2018).

Zhang, C., Freddolino, P. L. & Zhang, Y. COFACTOR: improved protein function prediction by combining structure, sequence and protein-protein interaction information. Nucleic Acids Res. 45, W291–W299 (2017).

Szklarczyk, D. et al. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 44, D380-384 (2016).

Duke, J. A. Dr. Duke’s Phytochemical and Ethnobotanical Databases. (2016). doi:10.15482/USDA.ADC/1239279

Szklarczyk, D. et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447–D452 (2015).

Marsden, P. A. et al. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett. 307, 287–293 (1992).

Fish, J. E. & Marsden, P. A. Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium. Cell. Mol. Life Sci. 63, 144–162 (2006).

Förstermann, U. & Münzel, T. Endothelial Nitric Oxide Synthase in Vascular Disease. Circulation 113, 1708–1714 (2006).

Denninger, J. W. & Marletta, M. A. Guanylate cyclase and the ⋅NO/cGMP signaling pathway. Biochim. Biophys. Acta BBA - Bioenerg. 1411, 334–350 (1999).

Surks, H. K. et al. Regulation of Myosin Phosphatase by a Specific Interaction with cGMP- Dependent Protein Kinase Iα. Science 286, 1583–1587 (1999).

Fukai, T. et al. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J. Clin. Invest. 105, 1631–1639 (2000).